Archived content

Day1  |  Day 2 |  Short CoursesDownload Brochure



12:30 pm Registration


2:00 Chairperson’s Opening Remarks

Reid Huber, Ph.D., Executive Director, Metabolic Endocrine Drug Development, Incyte Corporation

2:10 Modulating Lipid Metabolism

Cristina Rondinone, Ph.D., Director, Research, Metabolic Diseases, Roche Pharmaceuticals

2:40 FGF21 for Treatment of Metabolic Diseases

Jesper Gromada, Ph.D., Executive Director, Cardio-Vascular Metabolic Disease Area, Novartis Institutes for BioMedical Research

Fibroblast growth factor 21 (FGF21) is a potent metabolic regulator and a promising novel therapy for cardiovascular diseases, obesity and type 2 diabetes. In this talk I will review the preclinical pharmacology contributing to the actions of FGF21. A special emphasis will be placed on the molecular mechanisms by which FGF21 maintains energy homeostasis. In addition, knowledge gaps and challenges for further exploration of the therapeutic potential of this molecule will be addressed.

3:10 The Tipping Point between Life and Death of ER Stressed Pacreatic Beta Cells

Fumihiko Urano, M.D., Ph.D., Associate Professor of Molecular Medicine, University of Massachussetts Medical School


3:40 Networking Refreshment Break in the Exhibit Hall

4:20 Liver-directed Thyroid Beta Agonist for Targeting Cardio-metabolic Disease

Rebecca Taub, M.D., Senior Vice President, Research & Development, VIA Pharmaceuticals

VIA-3196, a liver-directed thyroid hormone beta agonist has the potential to provide benefit to patients with cardiometabolic risk including diabetics and dislipidemics. VIA-3196 lowers LDL cholesterol alone or in synergy with statins by greater than 40% in preclinical models, and reduces plasma triglicerides. VIA-3196 reduces hepatic triglicerides, a major cause of liver insulin resistance and non-alcoholic steatohepatitis. In animal models of diabetes and insulin reistance, VIA-3196 improves insulin sensitivity and lowers glucose to a similar level as rosiglitazone without causing weight gain.

4:50 Sponsored Presentation
(Sponsorship Opportunity Available)

5:20 Targeting the Gut for the Treatment of Metabolic Diseases

Andrew Swick, Ph.D., Senior Consultant, Illuminate BioPharma Consulting, LLC

5:50 Inhibiting Enterocytic MTP for Treatment of Diabetes and Metabolic Syndrome

Paul Sweetnam, Ph.D., Chief Scientific Officer, Surface Logix

SLx-4090 is a potent and selective small molecule inhibitor of microsomal triglyceride transfer protein (MTP). The compound was specifically designed to maximize therapeutic activity by targeting the enterocyte/intestinal wall while eliminating potential adverse effects associated with the inhibition of hepatic and/or cardiac MTP. Initial (2 week) clinical trials designed to explore the safety and effectiveness of this strategy indicated that SLx-4090 was well tolerated with no indication of LFT alterations. SLx-4090 was effective in reducing postprandial plasma triglycerides, chylomicrons and fasting LDL levels.    

6:20 Close of Day

Day1  |  Day 2 |  Short Courses 


Suggested Event Package (November 1 – 4):

November 1

Pre-Conference Short Courses:

Targeting GPCRs and Ion Channels with Antibodies (SC2)

November 2 - 3


Ion Channels as Therapeutic Targets OR GPCR-Based Drug Discovery

November 3 - 4


Targeting Diabetes with Novel Therapeutics

DOT Hub Icon 

 Short Courses

2015 Discovery on Target Brochure  





Molecular Sensing

Rosa Drug Development Advisors






The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager


September 21 

Next-Generation Histone Deacetylase Inhibitors Symposia 

Strategies for Rare Diseases Symposia 

September 22 

Developing CRISPR-Based Therapies Symposia 

September 22 - 23 

Targeting Epigenetic Readers and Chromatin Remodelers 

Targeting the Ubiquitin Proteasome System 

Targeting the Microbiome 

GPCR - Based Drug Discovery - Part 1 

Antibodies Against Membrane Protein Targets - Part 1 

RNAi for Functional Genomics Screening 

Gene Therapy Breakthroughs 

Targeting Ocular Disorders 

September 23 - 24 

Targeting Histone Methyltransferases and Demethylases 

Targeting the Unfolded Protein Response 

Kinase Inhibitor Discovery 

GPCR-Based Drug Discovery - Part 2 

Antibodies Against Membrane Protein Targets - Part 2 

New Frontiers in Gene Editing 

Quantitative Systems Pharmacology 

Short Courses 

SC1: Cancer Metabolism: Pathways, Targets and Clinical Updates 

SC2: Leveraging Data and Analytics for Drug DiSCovery 

SC3: Setting Up Effective Rnai SCreens: From Design to Data to Validation 

SC4: Phenotypic SCreening and Chemical Probe Development 

SC5: GPCR Structure-based Drug Discovery 

SC6: Targeting of GPCRs with Monoclonal Antibodies 

SC7: Setting Up Effective Functional SCreens Using 3D Cell Cultures 

SC8: Targeting Protein-protein Interactions: Biophysical Approaches 

SC9: Preclinical Animal Models for Ocular Indications 

SC10: Introduction to Allosteric Modulators and Biased Ligands of GPCRs 

SC11: Introduction to Targeted Covalent Inhibitors 

SC12: Assays and High-throughput SCreening for Novel Epigenetic Inhibitors 

SC13: Gamification and Drug Target Challenges 

SC14: A Primer to Gene Editing: Tools and Applications 

SC15: Using Mechanistic Physiological Models In Drug Development